Stockscreener 앱 받기
0.5015
5.60%
0.0265
전일 마감가:
$0.475
열려 있는:
$0.475
하루 거래량:
178.59K
Relative Volume:
1.04
시가총액:
$46.66M
수익:
$1.29M
순이익/손실:
$-29.87M
주가수익비율:
-1.3931
EPS:
-0.36
순현금흐름:
$-14.70M
1주 성능:
+8.34%
1개월 성능:
-5.77%
6개월 성능:
-16.40%
1년 성능:
-43.70%
1일 변동 폭
$0.475
$0.5162
1주일 범위
$0.465
$0.545
52주 변동 폭
$0.42
$0.90
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
VNRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.5017 | 46.66M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
423.25 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
198.87 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
478.72 | 35.17B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
109.12 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.83 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
VolitionRx enters new sales agreement, terminates old one - Investing.com Australia
VolitionRx enters new sales agreement, terminates old one By Investing.com - Investing.com South Africa
VolitionRX Ltd (AMEX: VNRX): An Enticing Stock To Watch - stocksregister.com
Insider Buying: Reynolds Cameron John, VolitionRX Ltd [VNRX] President and CEO invested 181,818 shares - knoxdaily.com
H.C. Wainwright maintains buy on VolitionRX with $2.50 target By Investing.com - Investing.com South Africa
VolitionRx (NYSE:VNRX) Coverage Initiated at HC Wainwright - The AM Reporter
What is HC Wainwright’s Estimate for VolitionRx Q1 Earnings? - Defense World
VolitionRX stock holds as Benchmark maintains rating - Investing.com Australia
VolitionRx (NYSE:VNRX) Now Covered by Analysts at HC Wainwright - Defense World
VolitionRX stock holds as Benchmark maintains rating By Investing.com - Investing.com South Africa
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
HC Wainwright Initiates VolitionRx With Buy Rating, $2.50 Price Target - marketscreener.com
VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
VolitionRx Moves to Register Warrant Shares on New Form By Investing.com - Investing.com South Africa
VolitionRx Moves to Register Warrant Shares on New Form - Investing.com
VolitionRx Limited (AMEX:VNRX) Q4 2024 Earnings Call Transcript - Insider Monkey
VolitionRx Ltd. Earnings Call Highlights Growth and Challenges - TipRanks
VolitionRX Ltd (VNRX) Reports Q4 EPS of -0.06, Revenue Surges to $1.2 Million, Exceeding Estimates - GuruFocus
VolitionRx (VNRX) Sees Strong Growth with Doubling of Nu.Q Vet T - GuruFocus
Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024 - Investing.com India
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances - Yahoo Finance
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong R - GuruFocus
VolitionRx Limited Reports Strong 2024 Financial Results - TipRanks
Volitionrx Ltd earnings missed, revenue fell short of estimates - Investing.com
Volitionrx Ltd earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024 By Investing.com - Investing.com UK
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update - Financial Times
A Look Ahead: VolitionRX's Earnings Forecast - Benzinga
Volition Announces Two Poster Presentations At Esmo's European Lung Cancer Congress 2025 - MarketScreener
Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Canada
VolitionRx CEO Cameron Reynolds acquires $99,999 in stock - Investing.com
Volitionrx director Innes buys $99,999 in common stock - Investing.com
VolitionRx CEO Cameron Reynolds acquires $99,999 in stock By Investing.com - Investing.com UK
VolitionRx secures up to $2.3 million in direct offering By Investing.com - Investing.com South Africa
VolitionRx secures up to $2.3 million in direct offering - Investing.com India
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering - Marketscreener.com
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update - Yahoo Finance
D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRX Reports Positive Results of Automated Nu.Q Cancer Immunoassay Test in Development - Marketscreener.com
VolitionRx reports results from Nu.Q Cancer test - TipRanks
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry - Yahoo Finance
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer - Yahoo Finance
Volitionrx announces pricing of public offering of 3.77 mln shares - Reuters
Volition Proudly Sponsors the 44th ISICEM Congress - Yahoo Finance
VolitionRx (VNRX) Projected to Post Quarterly Earnings on Monday - Defense World
D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRx expands cancer test deal with Fujifilm Vet Systems By Investing.com - Investing.com Australia
VolitionRx extends Nu.Q Vet Cancer Test automation agreement with Fujifilm - TipRanks
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
자본화:
|
볼륨(24시간):